A total of 126 eyes of 92 patients were studied, of whom 69 (75.0%) were female. At baseline, subjects' ages ranged from 59 to 96 years, with a mean age of 81.9 years (SD = 6.7). The mean duration of follow up was 20.4 months (SD = 11.7). Among the 126 eyes, 118 eyes (93.6%) presented with RPD at baseline. At baseline, the average measured area of GA was 2.8 mm
2 (SD = 2.9). 97.5% of the eyes with RPD showed GA progression, which ranged from 0 to 2.9 mm
2/y. Eighty-seven and half percent of the eyes without RPD had GA progression, which ranged from 0 to 2.6 mm
2/y. The mean measured GA progression rate for all the eyes included in this study was 0.8 mm
2/y (SD = 0.6), with a statistically significant difference between the unilobular and multilobular groups (0.3 mm
2/y vs. 0.9 mm
2/y,
P = 0.02). Most eyes with unilobular GA did not have RPD, while most eyes with multilobular GA did have RPD (28.6% with RPD vs. 97.5% with RPD, respectively).
Figure 3 shows progression rates in an eye with RPD and an eye without RPD.
Figure 4 exemplifies an eye with unilobular GA without RPD, as well as an eye with multilobular GA with concomitant RPD. Patients in the lower 50th percentile of initial measured GA area had a lower GA progression rate than patients in the upper 50th percentile (0.6 mm
2/y vs. 1.1 mm
2/y,
P < 0.001). The studied eyes had a mean initial lesion size of 4.4 and 4.0 mm
2 in the multilobular and unilobular GA groups, respectively (
P = 0.14). Sex did not prove to be a significant factor in GA progression rate (0.9 mm
2/y for females and 0.7 mm
2/y for males,
P = 0.28). Likewise, age did not prove to be a significant factor in GA progression, as patients in the lower 50th percentile of age had a progression rate similar to that of patients in the upper 50th percentile (0.9 mm
2/y and 0.8 mm
2/y, respectively,
P = 0.13). As illustrated in
Figure 5, superimposition of a modified Wisconsin grid on baseline NIR-R and/or FAF images and determination of the presence or absence of RPD in each of the five macular fields showed RPD in the central field in 106 eyes (84.1%), in the superior field in 103 eyes (81.7%), in the temporal field in 83 eyes (65.9%), in the inferior field in 84 eyes (66.7%), and in the nasal field in 83 eyes (65.9%). The
Table summarizes the extent of RPD in the study sample, showing the total number of eyes without RPD (8, or 6.3%) and with RPD in one macular field (7, or 5.6%), two macular fields (14, or 11.1%), three macular fields (21, or 16.7%), four macular fields (26, or 20.6%), and five macular fields (50, or 39.7%).